We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Agencourt® Receives Contract for National Cancer Institute's Office of Cancer Genomics

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agencourt® Receives Contract for National Cancer Institute's Office of Cancer Genomics"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Agencourt Bioscience Corporation has announced that its Genomic Services received a major sequencing contract for the National Cancer Institute (NCI), National Institutes of Health.

Under the agreement, NCI will supply Agencourt with normal and cancer tumor tissue samples and periodic lists of genes and targeted regions to be sequenced.

The goal of the project is to provide NCI research collaborators with a consistent, cost-effective, high-throughput sequencing resource. NCI collaborators who are working on cancer genomics research may request the sequencing of specific genes at any time. The initial term of the contract is one year, with an option to renew for a second year.

Collaborators will submit sequence trace data to the National Center for Biotechnology information (NCBI) and the base calls will be placed in a database managed by the NCI.

Agencourt will also develop a special web site that is accessible by project collaborators. This web site, with the posted information, will allow NCI collaborators to query the NCBI Trace database for additional metadata and relate it to other experimental results and clinical data by bio-specimen ID.

The project has been funded in whole or in part with federal funds from the National Cancer Institute.